

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 October 2005 (06.10.2005)

PCT

(10) International Publication Number  
**WO 2005/092858 A2**

(51) International Patent Classification<sup>7</sup>: **C07D 211/00**

(21) International Application Number:  
PCT/IB2005/000751

(22) International Filing Date: 16 March 2005 (16.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/557,598 29 March 2004 (29.03.2004) US

(71) Applicant (for JP only): **PFIZER JAPAN INC.** [JP/JP];  
Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Shibuya-ku.,  
Tokyo 151-8589, japan (JP).

(71) Applicant (for US only): **HASHIZUME, Yoshinobu**  
[JP/JP]; Pfizer Global Research and Development, 2, Aza  
5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393  
(JP).

(71) Applicant (for all designated States except JP, US):  
**PFIZER INC.** [US/US]; 235 East 42nd Street, New York,  
NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HIROTA, Masako**  
[JP/JP]; Pfizer Global Research and Development,  
Nagoya, Pfizer Japan Inc., 2 Aza 5-gochi, Taketoyo-cho,  
Chita-gun, Aichi-ken 470-2393 (JP). **MIHARA, Sachiko**  
[JP/JP]; Pfizer Global Research and Development, 2, Aza  
5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393  
(JP). **NAKAMURA, Hiroshi** [JP/JP]; Pfizer Global  
Research and Development, 2, Aza 5-gochi, Take-  
toyo-cho, Chita-gun, Aichi-ken 470-2393 (JP). **KOIKE,**

**Hiroki** [JP/JP]; Pfizer Global Research and development,  
Nagoya, Pfizer Japan Inc., 2, Aza 5-gochi, Taketoyo-cho,  
Chita-gun, Aichi-ken 470-2393 (JP). **MATSUMOTO,**  
**Yukari** [JP/JP]; Pfizer Global Research and development,  
Nagoya, Pfizer Japan Inc., 2, Aza 5-gochi, Taketoyo-cho,  
Chita-gun, Aichi-ken 470-2393 (JP).

(74) Agent: **FULLER, Grover, F., Jr.**; Pfizer Inc., 201 Tabor  
Road, Morris Plains, NJ 07950 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,  
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,  
ZM, ZW.


(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,  
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.


(54) Title: ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RE-  
CEPTOR ANTAGONIST



(I)

(57) Abstract: This invention provides the com-  
pounds of formula (I): or a pharmaceutically ac-  
ceptable ester of such compound, or a pharmaceu-  
tically acceptable salt thereof, wherein  $R^1$  and  $R^2$  in-  
dependently represent a hydrogen atom or the like;  
 $R^3$  represents a hydrogen atom, or the like;  $R^4$  rep-  
resents a hydrogen atom or the like; (formula II)  
represents one of the following or the like;  $R^5$  rep-  
resents an aryl group having from 6 to 10 ring atoms  
or the like;  $X$  represents an oxygen atom, or the

like;  $Y$  represents an oxygen atom or the like and  $n$  represents an integer 0, 1 or 2. These compounds have ORL1-receptor antagonist  
activity; and therefore, are useful to treat diseases or conditions such as pain, various CNS diseases etc.



WO 2005/092858 A2